E. Cohen-Jonathan Moyal / C. Toulas
Glioblastoma radioresistance: from signaling pathways to clinical trials
Our research project at a glance
Our team is a translational research team specialized in optimizing the radiotherapy treatment of glioblastoma (GBM). We first decipher the biological mechanisms of GBM radioresistance, then perform preclinical and clinical trials to evaluate the efficiency of combining radiotherapy with specific inhibitors of the radioresistance mechanisms we previously identified. We focus our research more particularly on the role of GBM stem cells in the tumor radioresistance.
Our team is a translational research team in radiobiology, specialized in optimizing the radiotherapy treatment of glioblastoma (GBM). Our research is conducted in 3 complementary approaches:
- first by deciphering the biological mechanisms of tumor radioresistance,
- by performing preclinical trials to validate targets for new radiosensitizer agents and to identify new predictive markers,
- finally by conceiving and performing early phase clinical trials performed in our Institute (IUCT) associating targeted drugs directed against the target identified in the lab with radiotherapy and integrating metabolic imaging studies, as well as surrogate biomarkers.
This 3-axis strategy to improve the GBM radiotherapy treatment efficiency is now amplified by strengthening our research on tumor heterogeneity and more particular on GBM radiation-induced migration and plasticity as well as GBM stem cells (GSC) involvement in GBM radioresistance.
This team also pursues its investigation concerning the mechanisms sustaining glioblastoma differentiated cells radioresistance by investigating the role of microenvironment factors as integrins and growth factors.
- Resistance to radiotherapy
- Stem cells
Labels and networks
Grants and funders
Oncotarget, 8 (34), pp. 56199-56209, 2017, ISSN: 1949-2553 (Electronic) 1949-2553 (Linking).
Oncotarget, 8 (37), pp. 60727-60749, 2017, ISSN: 1949-2553 (Electronic) 1949-2553 (Linking).
Oncotarget, 8 (35), pp. 58587-58600, 2017, ISSN: 1949-2553 (Electronic) 1949-2553 (Linking).
EANO guidelines for the diagnosis and treatment of meningiomas Journal Article
Lancet Oncol, 17 (9), pp. e383-91, 2016, ISSN: 1474-5488 (Electronic) 1470-2045 (Linking).
Cancer Res, 76 (10), pp. 3036-44, 2016, ISSN: 1538-7445 (Electronic) 0008-5472 (Linking).
Progastrin a new pro-angiogenic factor in colorectal cancer Journal Article
Oncogene, 34 (24), pp. 3120-30, 2015, ISSN: 1476-5594 (Electronic) 0950-9232 (Linking).
PLoS One, 10 (4), pp. e0123721, 2015, ISSN: 1932-6203 (Electronic) 1932-6203 (Linking).
Eur J Cancer, 50 (13), pp. 2351-9, 2014, ISSN: 1879-0852 (Electronic) 0959-8049 (Linking).
Cell Death Dis, 5 , pp. e1543, 2014, ISSN: 2041-4889 (Electronic).
Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1 alpha and survivin in U87 cells Journal Article
Eur J Cancer, 49 (13), pp. 2884-91, 2013, ISSN: 1879-0852 (Electronic) 0959-8049 (Linking).